Result of AGM
29 April 2020 16:00 BST
Results of Annual General Meeting held on 29 April 2020
AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 10 - 13 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.
|RESOLUTION||VOTES FOR||% OF VOTES CAST||VOTES AGAINST||% OF VOTES CAST||VOTES CAST IN TOTAL||TOTAL VOTES CAST AS A % OF ISSUED SHARE CAPITAL||VOTES WITHHELD|
|1||To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2019||1,061,180,101||99.92||872,215||0.08||1,062,052,316||80.93%||7,121,452|
|2||To confirm dividends||1,058,995,786||99.10||9,598,531||0.90||1,068,594,317||81.43%||579,469|
|3||To reappoint PricewaterhouseCoopers LLP as Auditor||1,068,300,235||99.97||312,449||0.03||1,068,612,684||81.43%||560,776|
|4||To authorise the Directors to agree the remuneration of the Auditor||1,067,398,628||99.90||1,086,858||0.10||1,068,485,486||81.42%||687,961|
|5a||To re-elect Leif Johansson as a Director||1,065,113,167||99.69||3,276,071||0.31||1,068,389,238||81.42%||784,805|
|5b||To re-elect Pascal Soriot as a Director||1,067,248,723||99.90||1,033,124||0.10||1,068,281,847||81.41%||892,364|
|5c||To re-elect Marc Dunoyer as a Director||1,060,164,242||99.25||8,056,265||0.75||1,068,220,507||81.40%||952,979|
|5d||To re-elect Geneviève Berger as a Director||882,846,920||83.06||179,994,848||16.94||1,062,841,768||80.99%||6,331,650|
|5e||To re-elect Philip Broadley as a Director||1,066,048,992||99.79||2,190,705||0.21||1,068,239,697||81.41%||933,713|
|5f||To re-elect Graham Chipchase as a Director||1,062,682,507||99.48||5,520,936||0.52||1,068,203,443||81.40%||969,967|
|5g||To elect Michel Demaré as a Director||1,066,252,259||99.82||1,969,593||0.18||1,068,221,852||81.40%||951,558|
|5h||To re-elect Deborah DiSanzo as a Director||1,067,836,362||99.97||351,091||0.03||1,068,187,453||81.40%||985,957|
|5i||To re-elect Sheri McCoy as a Director||1,064,329,862||99.64||3,890,368||0.36||1,068,220,230||81.40%||951,792|
|5j||To re-elect Tony Mok as a Director||1,067,117,370||99.90||1,066,669||0.10||1,068,184,039||81.40%||989,371|
|5k||To re-elect Nazneen Rahman as a Director||1,067,376,963||99.92||821,467||0.08||1,068,198,430||81.40%||973,592|
|5l||To re-elect Marcus Wallenberg as a Director||955,082,665||89.42||113,060,725||10.58||1,068,143,390||81.40%||1,030,019|
|6||To approve the Annual Report on Remuneration for the year ended 31 December 2019||1,032,308,145||96.65||35,747,783||3.35||1,068,055,928||81.39%||1,118,038|
|7||To approve the Directors' Remuneration Policy||972,774,742||94.71||54,292,376||5.29||1,027,067,118||78.27%||42,106,679|
|8||To authorise limited political donations||1,038,907,152||97.75||23,872,400||2.25||1,062,779,552||80.99%||6,394,668|
|9||To authorise the Directors to allot shares||910,654,650||85.26||157,472,093||14.74||1,068,126,743||81.40%||1,046,979|
|10||To authorise the Directors to disapply pre-emption rights||1,058,066,972||99.23||8,200,338||0.77||1,066,267,310||81.26%||2,906,339|
|11||To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments||1,054,711,677||98.92||11,513,414||1.08||1,066,225,091||81.25%||2,948,557|
|12||To authorise the Company to purchase its own shares||1,051,131,060||98.41||16,950,800||1.59||1,068,081,860||81.39%||1,091,896|
|13||To reduce the notice period for general meetings||998,062,805||93.44||70,101,553||6.56||1,068,164,358||81.40%||1,008,865|
|14||To approve the 2020 Performance Share Plan||1,010,149,491||95.66||45,877,396||4.34||1,056,026,887||80.48%||13,147,356|
As at 27 April 2020, the number of issued shares of the Company was 1,312,240,429 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact firstname.lastname@example.org or visit www.rns.com.